The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer
Abstract
The aim of this review is to summarize current available information about the role of PI3K/AKT/mTOR signaling in head and neck cancer as a potential target for new therapy options. 90% of all head and neck cancers are squamous cell carcinomas (HNSCC). The most common genetic alteration is inactivation of p16 gene which is cyclin dependent kinase inhibitor 2A. HNSCC are divided into human papilloma virus (HPV) related and HPV-negative carcinomas. HPV related carcinomas of patients who do not have a history of tobacco and alcohol consumption have better prognosis. Until now, HNSCC are treated with surgical removal of cancer tissue in primary region and lymph nodes combined with radiotherapy, cytostatic drugs and in some cases, epidermal growth factor receptor (EGFR) targeted antibody cetuximab and programmed death receptor-1 (PD-1) antibodies. PI3K/AKT/mTOR signaling is active in over 90% of HNSCC, as a result of EGFR activation (47%), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations (8.6%), PIK3CA amplifications (14.2%), phosphatidylinositol 3-kinase (PI3K) overexpression (27.2%) and phosphatase and tensin homolog (PTEN) mutation (10-15%). Activated PI3K/AKT/mTOR signaling is related to radiotherapy and cytostatic drug resistance, likely through enhanced DNA-repair mechanisms. Inhibitors against PI3K, AKT and mammalian target of rapamycin (mTOR) have remarkable effects on tumor cell proliferation and radiotherapy sensitization in cell cultures and mouse models. Nevertheless, feedback mechanisms, like activation of AKT after mTOR treatment, reduce efficiency. Therefore, combined therapy should be investigated. PI3K, AKT and mTOR inhibitors achieved tumor response in 5.3%, 2.8% and 31% when given as monotherapy, respectively. When combined to cytostatic drugs, 29.2% and 43.5% of all patients showed a response to PI3K and mTOR inhibitors, respectively. A study investigating everolimus (Rad001) with cisplatin and radiotherapy has reported promising 2-year progression free survival and overall survival rates of 85% and 92%. Further clinical trials should follow.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Papillomaviruses and cancer: from basic studies to clinical application
zur Hausen, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc798 · Cited by 4,024
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Evidence for a Causal Association Between Human Papillomavirus and a Subset of Head and Neck Cancers
Gillison, M. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.9.709 · Cited by 3,101
The human papilloma virus-16 E7-oncoprotein is able to bind to the retinoblastoma gene product
Dyson, N., Howley, P. M., Münger, K., & Harlow, E. (1989) · Science · doi:10.1126/science.2537532 · Cited by 3,017
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast
Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,006
Human papillomavirus oncoproteins: pathways to transformation
Moody, C. A., & Laimins, L. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2886 · Cited by 1,751
Structure and transcription of human papillomavirus sequences in cervical carcinoma cells
Schwarz, E., Freese, U. K., Gissmann, L., Mayer, W., Roggenbuck, B., Stremlau, A., & Hausen, H. Z. (1985) · Nature · doi:10.1038/314111a0 · Cited by 1,483
Forastiere, A., Koch, W., Trotti, A., & Sidransky, D. (2001) · New England Journal of Medicine · doi:10.1056/nejmra001375 · Cited by 1,250
Yu, J. S. L., & Cui, W. (2016) · Development · doi:10.1242/dev.137075 · Cited by 1,135
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Burkhart, D. L., & Sage, J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2399 · Cited by 974
Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B.-S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1012 · Cited by 860
Sun, S.-Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 802
zur Hausen, H. (1991) · Science · doi:10.1126/science.1659743 · Cited by 784
Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis
Camps, M., Rückle, T., Ji, H., Ardissone, V., Rintelen, F., Shaw, J., Ferrandi, C., Chabert, C., Gillieron, C., Françon, B., et al. (2005) · Nature Medicine · doi:10.1038/nm1284 · Cited by 750
Current Cigarette Smoking Among Adults — United States, 2016
Jamal, A., Phillips, E., Gentzke, A. S., Homa, D. M., Babb, S. D., King, B. A., & Neff, L. J. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6702a1 · Cited by 737
Human Papillomaviruses and Their Possible Role in Squamous Cell Carcinomas
zur Hausen, H. (1977) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-66800-5_1 · Cited by 710
Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
Brennan, J. A., Boyle, J. O., Koch, W. M., Goodman, S. N., Hruban, R. H., Eby, Y. J., Couch, M. J., Forastiere, A. A., & Sidransky, D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503163321104 · Cited by 658
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Zhang, Y., Kwok-Shing Ng, P., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., de Velasco, G., Jeong, K. J., Akbani, R., Hadjipanayis, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.013 · Cited by 626
Class I PI3K in oncogenic cellular transformation
Zhao, L., & Vogt, P. K. (2008) · Oncogene · doi:10.1038/onc.2008.244 · Cited by 594
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
Lui, V. W. Y., Hedberg, M. L., Li, H., Vangara, B. S., Pendleton, K., Zeng, Y., Lu, Y., Zhang, Q., Du, Y., Gilbert, B. R., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0103 · Cited by 589
Forbes, S. A., Tang, G., Bindal, N., Bamford, S., Dawson, E., Cole, C., Kok, C. Y., Jia, M., Ewing, R., Menzies, A., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp995 · Cited by 573
Maira, S.-M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., Schnell, C., Guthy, D., Nagel, T., Wiesmann, M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0474 · Cited by 529
Current cigarette smoking among adults — United States, 2005–2014
Jamal, A., Homa, D. M., O’Connor, E., Babb, S. D., Caraballo, R. S., Singh, T., Hu, S. S., & King, B. A. (2015) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6444a2 · Cited by 528
Furet, P., Guagnano, V., Fairhurst, R. A., Imbach-Weese, P., Bruce, I., Knapp, M., Fritsch, C., Blasco, F., Blanz, J., Aichholz, R., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.007 · Cited by 483
Duensing, S. M., & Münger, K. (2002) · PubMed · Cited by 464
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Dienstmann, R., Rodon, J., Serra, V., & Tabernero, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0639 · Cited by 462
Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer.
Dassonville, O., Formento, J. L., Francoual, M., Ramaioli, A., Santini, J., Schneider, M., Demard, F., & Milano, G. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1873 · Cited by 415
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.
Kondapaka, S. B., Singh, S. S., Dasmahapatra, G. P., Sausville, E. A., & Roy, K. (2003) · PubMed · Cited by 407
Ihle, N. T., Williams, R., Chow, S., Chew, W., Berggren, M. I., Paine-Murrieta, G., Minion, D. J., Halter, R. J., Wipf, P., Abraham, R., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.763.3.7 · Cited by 313
Lin, J., Sampath, D., Nannini, M. A., Lee, B. B., Degtyarev, M., Oeh, J., Savage, H., Guan, Z., Hong, R., Kassees, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3072 · Cited by 294
Löning, T., Ikenberg, H., Becker, J., Gissmann, L., Hoepfer, I., & zur Hausen, H. (1985) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12265517 · Cited by 287
Hausen, H. Z., Meinhof, W., Scheiber, W., & Bornkamm, G. W. (1974) · International Journal of Cancer · doi:10.1002/ijc.2910130509 · Cited by 271
Zhang, L., Wu, J., Ling, M. T., Zhao, L., & Zhao, K.-N. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0361-x · Cited by 264
Jares, P., Fernández, P. L., Campo, E., Nadal, A., Bosch, F., Aiza, G., Nayach, I., Traserra, J., & Cardesa, A. (1994) · PubMed · Cited by 258
Liu, N., Rowley, B. R., Bull, C. O., Schneider, C., Haegebarth, A., Schatz, C. A., Fracasso, P. R., Wilkie, D. P., Hentemann, M., Wilhelm, S. M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0993-t · Cited by 258
Molinolo, A. A., Hewitt, S. M., Amornphimoltham, P., Keelawat, S., Rangdaeng, S., Meneses García, A., Raimondi, A. R., Jufe, R., Itoiz, M., Gao, Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1041 · Cited by 243
Inhibition of Bak-induced apoptosis by HPV-18 E6
Thomas, M., & Banks, L. (1998) · Oncogene · doi:10.1038/sj.onc.1202223 · Cited by 241
Veldman, T., Horikawa, I., Barrett, J. C., & Schlegel, R. (2001) · Journal of Virology · doi:10.1128/jvi.75.9.4467-4472.2001 · Cited by 237
PRAD-1 (CCND1)/Cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma
Callender, T., El‐Naggar, A. K., Lee, M. S., Frankenthaler, R. A., Luna, M. A., & Batsakis, J. G. (1994) · Cancer · doi:10.1002/1097-0142(19940701)74:1<152::aid-cncr2820740124>3.0.co;2-k · Cited by 235
Perifosine: Update on a novel Akt inhibitor
Gills, J. J., & Dennis, P. A. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0016-4 · Cited by 221
Larkins, E., Blumenthal, G. M., Yuan, W., He, K., Sridhara, R., Subramaniam, S., Zhao, H., Liu, C., Yu, J., Goldberg, K. B., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0496 · Cited by 218
Lechner, M., Frampton, G. M., Fenton, T., Feber, A., Palmer, G., Jay, A., Pillay, N., Forster, M., Cronin, M. T., Lipson, D., et al. (2013) · Genome Medicine · doi:10.1186/gm453 · Cited by 217
Pomel, V., Klicic, J., Covini, D., Church, D. D., Shaw, J. P., Roulin, K., Burgat-Charvillon, F., Valognes, D., Camps, M., Chabert, C., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0601598 · Cited by 205
Duensing, S. M., Duensing, A. U., Crum, C. P., & Münger, K. (2001) · PubMed · Cited by 200
Molife, L. R., Yan, L., Vitfell-Rasmussen, J., Zernhelt, A. M., Sullivan, D. M., Cassier, P. A., Chen, E., Biondo, A., Tetteh, E., Siu, L. L., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-1 · Cited by 183
Ndubaku, C. O., Heffron, T. P., Staben, S. T., Baumgardner, M., Blaquiere, N., Bradley, E., Bull, R., Do, S., Dotson, J., Dudley, D., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4003632 · Cited by 179
Broek, R. V., Mohan, S., Eytan, D. F., Chen, Z., & Waes, C. V. (2013) · Oral Diseases · doi:10.1111/odi.12206 · Cited by 177
mTOR as a Molecular Target in HPV-Associated Oral and Cervical Squamous Carcinomas
Molinolo, A. A., Marsh, C., El Dinali, M., Gangane, N., Jennison, K., Hewitt, S., Patel, V., Seiwert, T. Y., & Gutkind, J. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2824 · Cited by 173
Saura, C., Roda, D., Roselló, S., Oliveira, M., Macarulla, T., Pérez-Fidalgo, J. A., Morales-Barrera, R., Sanchis-García, J. M., Musib, L., Budha, N., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0512 · Cited by 172
Koutsodontis, G., Tentes, I., Papakosta, P., Moustakas, A., & Kardassis, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104130200 · Cited by 159
Pim, D., Massimi, P., Dilworth, S. M., & Banks, L. (2005) · Oncogene · doi:10.1038/sj.onc.1208935 · Cited by 156
Chemical modification of rapamycin: the discovery of SDZ RAD
Sedrani, R. C., Cottens, S., Kallen, J. A., & Schüler, W. (1998) · Transplantation Proceedings · doi:10.1016/s0041-1345(98)00587-9 · Cited by 147
Zerfass, K., Schulze, A., Spitkovsky, D., Friedman, V, Henglein, B., & Jansen-Dürr, P. (1995) · Journal of Virology · doi:10.1128/jvi.69.10.6389-6399.1995 · Cited by 147
Human papillomavirus type 16 E7 up-regulates AKT activity through the retinoblastoma protein
Menges, C. W., Baglia, L. A., Lapoint, R., & McCance, D. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0499 · Cited by 145
Burns, J. E., Baird, M., Clark, L., Burns, P. A., Edington, K. G., Chapman, C., Mitchell, R. T., Robertson, G., Soutar, D. S., & Parkinson, E. K. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.238 · Cited by 140
Hwang, E.-S., Nottoli, T., & DiMaio, D. (1995) · Virology · doi:10.1006/viro.1995.1395 · Cited by 140
Kiyota, N., Hasegawa, Y., Takahashi, S., Yokota, T., Yen, C.-J., Iwae, S., Shimizu, Y., Hong, R., Goto, M., Kang, J. H., et al. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.07.023 · Cited by 137
Pharmacodynamic Markers of Perifosine Efficacy
Hennessy, B. T., Lu, Y., Poradosu, E., Yu, Q., Yu, S., Hall, H. S., Carey, M. S., Ravoori, M. K., Gonzalez-Angulo, A. M., Birch, R., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0760 · Cited by 131
Argiris, A. E., Cohen, E. E. W., Karrison, T. G., Esparaz, B. T., Mauer, A. M., Ansari, R., Wong, S. J., Lu, Y. F., Pins, M., Dancey, J. E., et al. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.7.2874 · Cited by 126
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
Yu, Y., Savage, R. E., Eathiraj, S., Meade, J., Wick, M. J., Hall, T. G., Abbadessa, G., & Schwartz, B. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140479 · Cited by 123
Wang, Z., Martín, D., Molinolo, A., Patel, V., Iglesias‐Bartolomé, R., Degese, M. S., Vitale-Cross, L. A., Chen, Q., & Gutkind, J. S. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju215 · Cited by 113
Patel, V., Lahusen, T. J., Sy, T. H., Sausville, E. A., Gutkind, J. S., & Senderowicz, A. M. (2002) · PubMed · Cited by 99
van Kempen, P. M. W., Noorlag, R., Braunius, W. W., Stegeman, I., Willems, S. M., & Grolman, W. (2013) · Epigenetics · doi:10.4161/epi.26881 · Cited by 98
Kuo, K., Hsiao, C.-H., Lin, C., Kuo, L., Huang, S., & Lin, M.-C. (2008) · Modern Pathology · doi:10.1038/modpathol.3800979 · Cited by 92
Zhang, B., Spandau, D. F., & Roman, A. (2002) · Journal of Virology · doi:10.1128/jvi.76.1.220-231.2002 · Cited by 85
Contreras-Paredes, A., De la Cruz-Hernández, E., Martínez-Ramírez, I., Dueñas-González, A., & Lizano, M. (2009) · Virology · doi:10.1016/j.virol.2008.09.040 · Cited by 82
Role of Akt signaling in resistance to DNA-targeted therapy
Avan, A., Narayan, R. S., Giovannetti, E., & Peters, G. J. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i5.352 · Cited by 80
Jimeno, A., Bauman, J. E., Weissman, C., Adkins, D. R., Schnadig, I. D., Beauregard, P., Bowles, D. W., Spira, A. I., Levy, B. P., Seetharamu, N., et al. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2014.12.013 · Cited by 78
Zumsteg, Z. S., Morse, N., Krigsfeld, G. S., Gupta, G. P., Higginson, D. S., Lee, N. Y., Morris, L. G. T., Ganly, I., Shiao, S. L., Powell, S. N., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2245 · Cited by 76
Freudlsperger, C., Horn, D., Weißfuß, S. W., Weichert, W., Weber, K., Saure, D., Sharma, S., Dyckhoff, G., Grabe, N., Plinkert, P. K., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29328 · Cited by 69
Grünwald, V., Keilholz, U., Boehm, A., Guntinas‐Lichius, O., Hennemann, B., Schmoll, H., Ivanyi, P., Abbas, M., Lehmann, U., Koch, A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu571 · Cited by 64
Fury, M. G., Lee, N. Y., Sherman, E. J., Ho, A. L., Rao, S. D., Heguy, A., Shen, R., Korte, S. H., Lisa, D., Ganly, I., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.06.2043 · Cited by 61
Goel, A. N., Raghavan, G., John, M. A. S., & Long, J. L. (2018) · JAMA Facial Plastic Surgery · doi:10.1001/jamafacial.2018.1197 · Cited by 61
Foster, P., Yamaguchi, K., Hsu, P. P., Qian, F., Du, X., Wu, J., Won, K.-A., Yu, P., Jaeger, C. T., Zhang, W., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0833 · Cited by 58
Clark, C. A., Shah, S. H., Ferdinandez, L. H., Ekshyyan, O. Y., Abreo, F. W., Rong, X., McLarty, J. W., Lurie, A. A., Milligan, E. J., & Nathan, C. O. (2010) · The Laryngoscope · doi:10.1002/lary.20917 · Cited by 58
Saba, N. F., Hurwitz, S. J., Magliocca, K. R., Kim, S., Owonikoko, T. K., Harvey, D., Ramalingam, S. S., Chen, Z., Rogerio, J., Sheldon, J. M., et al. (2014) · Cancer · doi:10.1002/cncr.28965 · Cited by 54
Liu, Y., Wan, W.-Z., Li, Y., Zhou, G.-L., & Liu, X. (2016) · Oncotarget · doi:10.18632/oncotarget.12742 · Cited by 54
Holler, M., Grottke, A., Mueck, K., Manes, J., Jücker, M., Rodemann, H. P., & Toulany, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154745 · Cited by 52
Self-citationRodon, J. A., Curigliano, G., Delord, J., Harb, W. A., Azaro, A., Han, Y., Wilke, C., Donnet, V., Sellami, D. B., & Beck, T. (2018) · Oncotarget · doi:10.18632/oncotarget.25854 · Cited by 51
Gao, G., Johnson, S. H., Vasmatzis, G., Pauley, C. E., Tombers, N. M., Kasperbauer, J. L., & Smith, D. I. (2017) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22415 · Cited by 49
Human Papillomavirus and the Development of Different Cancers
Gao, G., & Smith, D. I. (2016) · Cytogenetic and Genome Research · doi:10.1159/000458166 · Cited by 46
Dunn, L. A., Fury, M. G., Xiao, H., Baxi, S. S., Sherman, E. J., Korte, S. H., Pfister, C., Haque, S. S., Katabi, N., Ho, A. L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx346 · Cited by 46
Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines
Ma, B. B. Y., Lui, V. W. Y., Hui, C. W. C., Lau, C. P. Y., Wong, C. H., Hui, E. P., Ng, M. H. L., Tsao, S. W., Li, Y., & Chan, A. T. �. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9896-5 · Cited by 45
Zheng, Z., Amran, S. I., Thompson, P. E., & Jennings, I. G. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.072546 · Cited by 44
Activating Akt1 mutations alter DNA double strand break repair and radiosensitivity
Oeck, S., Al-Refae, K., Riffkin, H., Wiel, G., Handrick, R., Klein, D., Iliakis, G. E., & Jendrossek, V. (2017) · Scientific Reports · doi:10.1038/srep42700 · Cited by 44
Fury, M. G., Sherman, E. J., Ho, A. L., Xiao, H., Tsai, F. Y.-C., Nwankwo, O., Sima, C. S., Heguy, A., Katabi, N., Haque, S. S., et al. (2013) · Cancer · doi:10.1002/cncr.27986 · Cited by 43
Ewald, F., Nörz, D. S., Grottke, A., Bach, J., Herzberger, C., Hofmann, B. T., Nashan, B., & Jücker, M. (2015) · Journal of Cancer · doi:10.7150/jca.12452 · Cited by 43
Self-citationProtein kinase B: emerging mechanisms of isoform-specific regulation of cellular signaling in cancer
Wadhwa, B., Makhdoomi, U. S., Vishwakarma, R. A., & Malik, F. A. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000496 · Cited by 41
Fury, M. G., Sherman, E. J., Ho, A. L., Katabi, N., Sima, C. S., Kelly, K. W., Nwankwo, O., Haque, S. S., & Pfister, D. G. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1894-y · Cited by 37
Liu, H., Li, J., Zhou, Y., Hu, Q., Zeng, Y., & Mehryar, M. M. (2016) · Journal of Medical Virology · doi:10.1002/jmv.24670 · Cited by 36
Wong, C. H., Ma, B. B. Y., Cheong, H. T., Hui, C. W. C., Hui, E. P., & Chan, A. T. �. (2015) · Europe PMC (PubMed Central) · Cited by 31
Wheler, J. J., Mutch, D. G., Lager, J. J., Castell, C., Liu, L., Jiang, J., & Traynor, A. M. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0257 · Cited by 30
Bowles, D. W., Senzer, N. N., Hausman, D. F., Peterson, S., Vo, A. C. H., Walker, L. N., Cohen, R. B., & Jimeno, A. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0124-3 · Cited by 23
Lin, X., Liao, J., Yang, Z., Fan, X., Cullen, K. J., Chen, L., & Dan, H. (2019) · PubMed Central · Cited by 19
Cintas, C., & Guillermet‐Guibert, J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2017.00330 · Cited by 17
Lu, X. J. D., Liu, K. Y. P., Soares, R. C., Thomson, T. A., Prisman, E., Wu, J., & Poh, C. F.-Y. (2018) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12779 · Cited by 13
Wienecke, A., & Kraywinkel, K. (2018) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-018-2821-0 · Cited by 13
Cited by
Oral squamous cell carcinomas: state of the field and emerging directions
Tan, Y., Wang, Z., Xu, M., Li, B., Huang, Z., Qin, S., Nice, E. C., Tang, J., & Huang, C. (2023) · International Journal of Oral Science · doi:10.1038/s41368-023-00249-w · Cited by 831
Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 253
Metadata
- Authors
- Marquard, F. E., & Jücker, M.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 172
- Pages
- 113729
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2991303558
- Cited by
- 270
- References
- 103
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.